Day Range2.250 - 2.390 | 52 Wk Range1.830 - 6.010 | Open / Close2.350 / 2.250 | Float / Outstanding45.130M / 55.474M |
Vol / Avg.266.583K / 160.025K | Mkt Cap124.816M | P/E- | 50d Avg. Price2.600 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float45.130M | EPS-2.290 |
Cellectis Stock (NASDAQ: CLLS) stock price, news, charts, stock research, profile.
Day Range2.250 - 2.390 | 52 Wk Range1.830 - 6.010 | Open / Close2.350 / 2.250 | Float / Outstanding45.130M / 55.474M |
Vol / Avg.266.583K / 160.025K | Mkt Cap124.816M | P/E- | 50d Avg. Price2.600 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float45.130M | EPS-2.290 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-02 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.450 | -0.580 | -0.1300 | ||||
REV | 13.430M | 1.921M | -11.509M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Cellectis (NASDAQ: CLLS) through any online brokerage.
Other companies in Cellectis’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Galectin Therapeutics (NASDAQ:GALT), Inozyme Pharma (NASDAQ:INZY), Immuneering (NASDAQ:IMRX) and Atossa Therapeutics (NASDAQ:ATOS).
The latest price target for Cellectis (NASDAQ: CLLS) was reported by JMP Securities on Thursday, January 19, 2023. The analyst firm set a price target for 6.00 expecting CLLS to rise to within 12 months (a possible 166.67% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Cellectis (NASDAQ: CLLS) is $2.25 last updated February 8, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Cellectis.
Cellectis’s Q4 earnings are confirmed for Thursday, March 2, 2023.
There is no upcoming split for Cellectis.
Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Cellectis Stock (NASDAQ: CLLS) stock price, news, charts, stock research, profile.
Day Range2.250 - 2.390 | 52 Wk Range1.830 - 6.010 | Open / Close2.350 / 2.250 | Float / Outstanding45.130M / 55.474M |
Vol / Avg.266.583K / 160.025K | Mkt Cap124.816M | P/E- | 50d Avg. Price2.600 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float45.130M | EPS-2.290 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-02 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.450 | -0.580 | -0.1300 | ||||
REV | 13.430M | 1.921M | -11.509M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Cellectis (NASDAQ: CLLS) through any online brokerage.
Other companies in Cellectis’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Galectin Therapeutics (NASDAQ:GALT), Inozyme Pharma (NASDAQ:INZY), Immuneering (NASDAQ:IMRX) and Atossa Therapeutics (NASDAQ:ATOS).
The latest price target for Cellectis (NASDAQ: CLLS) was reported by JMP Securities on Thursday, January 19, 2023. The analyst firm set a price target for 6.00 expecting CLLS to rise to within 12 months (a possible 166.67% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Cellectis (NASDAQ: CLLS) is $2.25 last updated February 8, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Cellectis.
Cellectis’s Q4 earnings are confirmed for Thursday, March 2, 2023.
There is no upcoming split for Cellectis.
Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Cellectis Stock (NASDAQ: CLLS) stock price, news, charts, stock research, profile.
Day Range2.250 - 2.390 | 52 Wk Range1.830 - 6.010 | Open / Close2.350 / 2.250 | Float / Outstanding45.130M / 55.474M |
Vol / Avg.266.583K / 160.025K | Mkt Cap124.816M | P/E- | 50d Avg. Price2.600 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float45.130M | EPS-2.290 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-02 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.450 | -0.580 | -0.1300 | ||||
REV | 13.430M | 1.921M | -11.509M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Cellectis (NASDAQ: CLLS) through any online brokerage.
Other companies in Cellectis’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Galectin Therapeutics (NASDAQ:GALT), Inozyme Pharma (NASDAQ:INZY), Immuneering (NASDAQ:IMRX) and Atossa Therapeutics (NASDAQ:ATOS).
The latest price target for Cellectis (NASDAQ: CLLS) was reported by JMP Securities on Thursday, January 19, 2023. The analyst firm set a price target for 6.00 expecting CLLS to rise to within 12 months (a possible 166.67% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Cellectis (NASDAQ: CLLS) is $2.25 last updated February 8, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Cellectis.
Cellectis’s Q4 earnings are confirmed for Thursday, March 2, 2023.
There is no upcoming split for Cellectis.
Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Cellectis Stock (NASDAQ: CLLS) stock price, news, charts, stock research, profile.
Day Range2.250 - 2.390 | 52 Wk Range1.830 - 6.010 | Open / Close2.350 / 2.250 | Float / Outstanding45.130M / 55.474M |
Vol / Avg.266.583K / 160.025K | Mkt Cap124.816M | P/E- | 50d Avg. Price2.600 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float45.130M | EPS-2.290 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-02 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.450 | -0.580 | -0.1300 | ||||
REV | 13.430M | 1.921M | -11.509M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Cellectis (NASDAQ: CLLS) through any online brokerage.
Other companies in Cellectis’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Galectin Therapeutics (NASDAQ:GALT), Inozyme Pharma (NASDAQ:INZY), Immuneering (NASDAQ:IMRX) and Atossa Therapeutics (NASDAQ:ATOS).
The latest price target for Cellectis (NASDAQ: CLLS) was reported by JMP Securities on Thursday, January 19, 2023. The analyst firm set a price target for 6.00 expecting CLLS to rise to within 12 months (a possible 166.67% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Cellectis (NASDAQ: CLLS) is $2.25 last updated February 8, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Cellectis.
Cellectis’s Q4 earnings are confirmed for Thursday, March 2, 2023.
There is no upcoming split for Cellectis.
Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Cellectis Stock (NASDAQ: CLLS) stock price, news, charts, stock research, profile.
Day Range2.250 - 2.390 | 52 Wk Range1.830 - 6.010 | Open / Close2.350 / 2.250 | Float / Outstanding45.130M / 55.474M |
Vol / Avg.266.583K / 160.025K | Mkt Cap124.816M | P/E- | 50d Avg. Price2.600 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float45.130M | EPS-2.290 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-02 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.450 | -0.580 | -0.1300 | ||||
REV | 13.430M | 1.921M | -11.509M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Cellectis (NASDAQ: CLLS) through any online brokerage.
Other companies in Cellectis’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Galectin Therapeutics (NASDAQ:GALT), Inozyme Pharma (NASDAQ:INZY), Immuneering (NASDAQ:IMRX) and Atossa Therapeutics (NASDAQ:ATOS).
The latest price target for Cellectis (NASDAQ: CLLS) was reported by JMP Securities on Thursday, January 19, 2023. The analyst firm set a price target for 6.00 expecting CLLS to rise to within 12 months (a possible 166.67% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Cellectis (NASDAQ: CLLS) is $2.25 last updated February 8, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Cellectis.
Cellectis’s Q4 earnings are confirmed for Thursday, March 2, 2023.
There is no upcoming split for Cellectis.
Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Cellectis Stock (NASDAQ: CLLS) stock price, news, charts, stock research, profile.
Day Range2.250 - 2.390 | 52 Wk Range1.830 - 6.010 | Open / Close2.350 / 2.250 | Float / Outstanding45.130M / 55.474M |
Vol / Avg.266.583K / 160.025K | Mkt Cap124.816M | P/E- | 50d Avg. Price2.600 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float45.130M | EPS-2.290 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-02 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.450 | -0.580 | -0.1300 | ||||
REV | 13.430M | 1.921M | -11.509M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Cellectis (NASDAQ: CLLS) through any online brokerage.
Other companies in Cellectis’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Galectin Therapeutics (NASDAQ:GALT), Inozyme Pharma (NASDAQ:INZY), Immuneering (NASDAQ:IMRX) and Atossa Therapeutics (NASDAQ:ATOS).
The latest price target for Cellectis (NASDAQ: CLLS) was reported by JMP Securities on Thursday, January 19, 2023. The analyst firm set a price target for 6.00 expecting CLLS to rise to within 12 months (a possible 166.67% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Cellectis (NASDAQ: CLLS) is $2.25 last updated February 8, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Cellectis.
Cellectis’s Q4 earnings are confirmed for Thursday, March 2, 2023.
There is no upcoming split for Cellectis.
Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Cellectis Stock (NASDAQ: CLLS) stock price, news, charts, stock research, profile.
Day Range2.250 - 2.390 | 52 Wk Range1.830 - 6.010 | Open / Close2.350 / 2.250 | Float / Outstanding45.130M / 55.474M |
Vol / Avg.266.583K / 160.025K | Mkt Cap124.816M | P/E- | 50d Avg. Price2.600 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float45.130M | EPS-2.290 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-02 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.450 | -0.580 | -0.1300 | ||||
REV | 13.430M | 1.921M | -11.509M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Cellectis (NASDAQ: CLLS) through any online brokerage.
Other companies in Cellectis’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Galectin Therapeutics (NASDAQ:GALT), Inozyme Pharma (NASDAQ:INZY), Immuneering (NASDAQ:IMRX) and Atossa Therapeutics (NASDAQ:ATOS).
The latest price target for Cellectis (NASDAQ: CLLS) was reported by JMP Securities on Thursday, January 19, 2023. The analyst firm set a price target for 6.00 expecting CLLS to rise to within 12 months (a possible 166.67% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Cellectis (NASDAQ: CLLS) is $2.25 last updated February 8, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Cellectis.
Cellectis’s Q4 earnings are confirmed for Thursday, March 2, 2023.
There is no upcoming split for Cellectis.
Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Cellectis Stock (NASDAQ: CLLS) stock price, news, charts, stock research, profile.
Day Range2.250 - 2.390 | 52 Wk Range1.830 - 6.010 | Open / Close2.350 / 2.250 | Float / Outstanding45.130M / 55.474M |
Vol / Avg.266.583K / 160.025K | Mkt Cap124.816M | P/E- | 50d Avg. Price2.600 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float45.130M | EPS-2.290 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-02 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.450 | -0.580 | -0.1300 | ||||
REV | 13.430M | 1.921M | -11.509M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Cellectis (NASDAQ: CLLS) through any online brokerage.
Other companies in Cellectis’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Galectin Therapeutics (NASDAQ:GALT), Inozyme Pharma (NASDAQ:INZY), Immuneering (NASDAQ:IMRX) and Atossa Therapeutics (NASDAQ:ATOS).
The latest price target for Cellectis (NASDAQ: CLLS) was reported by JMP Securities on Thursday, January 19, 2023. The analyst firm set a price target for 6.00 expecting CLLS to rise to within 12 months (a possible 166.67% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Cellectis (NASDAQ: CLLS) is $2.25 last updated February 8, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Cellectis.
Cellectis’s Q4 earnings are confirmed for Thursday, March 2, 2023.
There is no upcoming split for Cellectis.
Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Cellectis Stock (NASDAQ: CLLS) stock price, news, charts, stock research, profile.
Day Range2.250 - 2.390 | 52 Wk Range1.830 - 6.010 | Open / Close2.350 / 2.250 | Float / Outstanding45.130M / 55.474M |
Vol / Avg.266.583K / 160.025K | Mkt Cap124.816M | P/E- | 50d Avg. Price2.600 |
Div / Yield (Forward)- / -% | Payout Ratio- | Total Float45.130M | EPS-2.290 |
Q4 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-03-02 | ||||||
REV |
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.450 | -0.580 | -0.1300 | ||||
REV | 13.430M | 1.921M | -11.509M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Cellectis (NASDAQ: CLLS) through any online brokerage.
Other companies in Cellectis’s space includes: Syros Pharmaceuticals (NASDAQ:SYRS), Galectin Therapeutics (NASDAQ:GALT), Inozyme Pharma (NASDAQ:INZY), Immuneering (NASDAQ:IMRX) and Atossa Therapeutics (NASDAQ:ATOS).
The latest price target for Cellectis (NASDAQ: CLLS) was reported by JMP Securities on Thursday, January 19, 2023. The analyst firm set a price target for 6.00 expecting CLLS to rise to within 12 months (a possible 166.67% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Cellectis (NASDAQ: CLLS) is $2.25 last updated February 8, 2023 at 9:00 PM UTC.
There are no upcoming dividends for Cellectis.
Cellectis’s Q4 earnings are confirmed for Thursday, March 2, 2023.
There is no upcoming split for Cellectis.
Cellectis is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.